Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing data from patients with drug reaction with eosinophilia and systemic symptoms to antibiotics

ABSTRACT: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a cutaneous drug hypersensitivity reaction (DHR) with internal organ involvement and associated mortality, often caused by antibiotics. Despite the risk of severe systemic involvement, no robust diagnostic test to identify causative drug exists. To identify potential biomarkers, we evaluated changes in gene expression following exposure of PBMCs to a culprit antibiotic (cefoxitin, teicoplanin, vancomycin, dapsone) and developed a molecular assay test (MAT).

ORGANISM(S): Homo sapiens

PROVIDER: GSE160369 | GEO | 2023/05/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene transcription in carbamazepine- and minocycline-induced DRESS

2010-07-21 | GSE23015 | GEO

Gene transcription in carbamazepine- and minocycline-induced DRESS

Project description:Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe, drug-induced reaction that involves both the skin and viscera. To understand the immunological components of DRESS, we prospectively assessed 40 DRESS patients. The patients were evaluated for phenotype, cytokine secretion, repertoire of CD4+ and CD8+ peripheral blood T lymphocytes and viral reactivation. A subgroup of patients was analyzed using microarrays. Patients with carbamazepine- or minocycline- induced DRESS were pooled separately for analysis. RNA from total PBMCs and CD4+ and CD8+-sorted blood T cells was amplified. Expression of 894 genes of immunological interest was analyzed with a PIQOR TM arrays (Miltenyi). Gene expression was individually compared between day 0 and 90 in the minocycline-induced DRESS patients. Control groups included patients taking minocycline carbamazepine, and healthy patients without medication.

2010-07-21 | E-GEOD-23015 | biostudies-arrayexpress

RNA sequencing data from patients with drug reaction with eosinophilia and systemic symptoms to antibiotics

Project description:RNA sequencing data from patients with drug reaction with eosinophilia and systemic symptoms to antibiotics

| PRJNA673125 | ENA

Post-epidemic eosinophilia myalgia syndrome associated with L-Tryptophan

Project description:Eosinophilia–myalgia syndrome (EMS) is characterized by subacute onset of myalgias and peripheral eosinophilia, followed by chronic neuropathy and skin induration. The EMS epidemic in 1989 was linked to L-tryptophan consumption originating from a single source. Following the Food and Drug Administration (FDA) ban on the sale of L-tryptophan, the incidence of EMS declined rapidly. Moreover, no new cases have been published since the FDA ban was lifted in 2005. We report the clinical, histopathological and immunogenetic features of a new case of L-tryptophan-associated EMS along with evidence of activated transforming growth factor-ß and interleukin-4 signaling in the lesional skin. 6 samples were analyzed to include EMS patient and two replicates along with three normal controls

2012-01-28 | E-GEOD-26934 | biostudies-arrayexpress

Post-epidemic eosinophilia myalgia syndrome associated with L-Tryptophan

2012-01-28 | GSE26934 | GEO

Recurrent activating STAT5B N642H mutations in myeloid neoplasms with eosinophilia

Project description:Whole transcriptome sequencing (RNAseq) of 14 cases with suspected primary eosinophilia was performed to identify recurrent mutations which could be used as new diagnostic and prognostic markers as well as potential targets for therapy.

2019-01-12 | E-MTAB-7492 | biostudies-arrayexpress

Study of the impact of Anti-IL5 neutralizing antibodies on bone marrow eosinophil maturation stages during IL-33 induced eosinophilia.

Project description:RNA-seq of the 4 eosinophil maturation stages in the murine bone marrow during Interleukin-33 induced eosinophilia combined with Anti-IL5 or Control isotype injections.

2024-05-21 | GSE248712 | GEO

RNA-seq of the 4 stages of maturation of eosinophils in the murine bone marrow in the steady state and in Interleukin-33- induced eosinophilia.

Project description:Study of the transcriptional changes occurring during eosinophil maturation in the steady state and in IL-33 induced eosinophilia.

2024-05-21 | GSE229824 | GEO

Approach to Eosinophilia Presenting With Pulmonary Symptoms.

Project description:Eosinophilia with pulmonary involvement is characterized by the presence of peripheral blood eosinophilia, typically ≥500 cells/mm3, by pulmonary symptoms and physical examination findings that are nonspecific, and by radiographic evidence of pulmonary disease and is further supported by histopathologic evidence of tissue eosinophilia in a lung or pleura biopsy specimen and/or increased eosinophils in BAL fluid, usually >10%. Considering that there are a variety of underlying causes of eosinophilia with pulmonary manifestations and overlapping clinical, laboratory, and radiologic features, it is essential to approach the evaluation of eosinophilia with pulmonary findings systematically. In this review, we will describe a case presentation and discuss the differential diagnosis, a directed approach to the diagnostic evaluation and supporting literature, the current treatment strategies for pulmonary eosinophilia syndromes, and the levels of evidence underlying the recommendations, where available. Overall, optimal management of eosinophilic lung disease presentations are directed at the underlying cause when identifiable, and the urgency of treatment may be guided by the presence of severe end-organ involvement or life-threatening complications. When an underlying cause is not easily attributable, management of eosinophilia with pulmonary involvement largely relies on eosinophil-directed interventions, for which biologic therapies are increasingly being used.

| S-EPMC8039005 | biostudies-literature

Recurrent activating STAT5B N642H mutations in myeloid neoplasms with eosinophilia

Project description:Recurrent activating STAT5B N642H mutations in myeloid neoplasms with eosinophilia

| PRJEB30454 | ENA